Impact of the Physiological Effects of Aging on the Pharmacokinetics and Pharmacodynamics of Systemic Lung Cancer Treatment

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/978-0-85729-793-8_5
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Severe docetaxel overdose induced by pharmacokinetic interaction with dronedarone.

  2011cited by this paper
• Unanswered questions: monoclonal antibodies in the treatment of advanced non-small-cell lung cancer.

  2010cited by this paper
• Comorbidity and polypharmacy in elderly cancer patients: The significance on treatment outcome and tolerance

  2010cited by this paper
• Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers.

  2009cited by this paper
• Pemetrexed in the treatment of advanced non-squamous lung cancer.

  2009cited by this paper
• Clinical pharmacokinetics of tyrosine kinase inhibitors.

  2009cited by this paper
• Safety profile of erlotinib in patients with advanced non-small cell lung cancer with chronic renal failure.

  2007cited by this paper
• Is genetic testing for cytochrome P450 polymorphisms ready for implementation?

  2007cited by this paper
• Evaluation of the Absolute Oral Bioavailability and Bioequivalence of Erlotinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in a Randomized, Crossover Study in Healthy Subjects

  2006cited by this paper
• Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762).

  2006cited by this paper
• Pharmacokinetics and Toxicity of Weekly Docetaxel in Older Patients

  2006cited by this paper
• Safety profile of gefitinib in advanced non-small cell lung cancer elderly patients with chronic renal failure: two clinical cases.

  2005cited by this paper
• Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer.

  2005cited by this paper
• Pharmacokinetic Drug Interactions of Gefitinib with Rifampicin, Itraconazole and Metoprolol

  2005cited by this paper
• Cytochrome P450-dependent metabolism of gefitinib

  2005cited by this paper
• Relation between age and clearance rate of nine investigational anticancer drugs from phase I pharmacokinetic data

  2004cited by this paper
• Comparison of pharmacokinetics and pharmacodynamics of docetaxel and Cisplatin in elderly and non-elderly patients: why is toxicity increased in elderly patients?

  2004cited by this paper
• Etoposide dosage and pharmacodynamics

  2004cited by this paper
• Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

  2004cited by this paper
• Cisplatin nephrotoxicity

  2004cited by this paper
• FDA drug approval summaries: pemetrexed (Alimta).

  2004cited by this paper
• Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients.

  2003cited by this paper
• Pemetrexed (Alimta, MTA, multitargeted antifolate, LY231514) for malignant pleural mesothelioma.

  2003cited by this paper
• Altered clearance of unbound paclitaxel in elderly patients with metastatic breast cancer.

  2003cited by this paper
• Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors.

  2003cited by this paper
• Pharmacokinetics and pharmacodynamics: maximizing the clinical potential of Erlotinib (Tarceva).

  2003cited by this paper
• Carboplatin dosing formulae: gender bias and the use of creatinine-based methodologies.

  2002cited by this paper
• Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition.

  2002cited by this paper
• Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer.

  2002cited by this paper
• Pharmacokinetic Considerations of Oral Chemotherapy in Elderly Patients with Cancer

  2002cited by this paper
• A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer.

  2001cited by this paper
• Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.

  2001cited by this paper
• Pharmacokinetics and Tolerability of the Orally Active Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 in Healthy Volunteers

  2001cited by this paper
• Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients.

  2001cited by this paper
• Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer.

  2001cited by this paper
• Renal Tolerance to Cisplatin in Patients 70 Years and Older

  2001cited by this paper
• Population Pharmacokinetics and Pharmacokinetic-Pharmacodynamic Relationships for Docetaxel

  2001cited by this paper
• Reduction of paclitaxel-induced peripheral neuropathy with glutamine.

  2001cited by this paper
• Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565.

  2000cited by this paper
• Pharmacology of antineoplastic agents in older cancer patients.

  2000cited by this paper
• Bayesian estimate of vinorelbine pharmacokinetic parameters in elderly patients with advanced metastatic cancer.

  2000cited by this paper
• Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma

  2000cited by this paper
• A phase I dose escalation study of epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor CP-358,774 in patients (pts) with advanced solid tumors

  2000cited by this paper
• Irinotecan therapy in adults with recurrent or progressive malignant glioma.

  1999cited by this paper
• Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice.

  1999cited by this paper
• Pharmacological analysis of etoposide in elderly patients with lung cancer.

  1999cited by this paper
• A multicenter, Phase II trial of weekly irinotecan (CPT‐11) in patients with previously treated colorectal carcinoma

  1999cited by this paper
• Clinically relevant drug-drug interactions in oncology.

  1998cited by this paper
• Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer.

  1998cited by this paper
• Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.

  1998cited by this paper
• Irinotecan in the first-line treatment of colorectal cancer.

  1998cited by this paper
• Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.

  1998cited by this paper
• Review : Topoisomerase I inhibitors: 2. Irinotecan

  1998cited by this paper
• Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264.

  1998cited by this paper
• Polypharmacy in the elderly. Early intervention can prevent complications.

  1997cited by this paper
• Review : Topoisomerase I inhibitors: 1. Topotecan

  1997cited by this paper
• Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062).

  1997cited by this paper
• Pharmacokinetics and tolerance of vinorelbine in elderly patients with metastatic breast cancer.

  1997cited by this paper
• Cancer chemotherapy in the older patient

  1997cited by this paper
• LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes.

  1997cited by this paper
• Age and cytochrome P450‐linked drug metabolism in humans: An analysis of 226 subjects with equal histopathologic conditions

  1997cited by this paper
• Life-threatening myelosuppression in patients with occult renal impairment receiving topotecan.

  1997cited by this paper
• Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer.

  1996cited by this paper
• Pharmacokinetics of vinorelbine in patients with liver metastases

  1996cited by this paper
• Optimal use of docetaxel (Taxotere®): maximizing its potential

  1996cited by this paper
• Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function.

  1995cited by this paper
• Pharmacokinetic Drug Interactions with Anticancer Drugs

  1994cited by this paper
• Renal tolerance of cisplatin in patients more than 80 years old.

  1994cited by this paper
• Carboplatin dosage: prospective evaluation of a simple formula based on renal function.

  1989cited by this paper
• Cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer: the elimination of age trends in toxicity by using doses based on creatinine clearance.

  1984cited by this paper
• Prediction of Creatinine Clearance from Serum Creatinine

  1976cited by this paper
• Textbook of geriatric medicine and gerontology

  1973cited by this paper

• Immunotherapy for Elderly Patients with Advanced Non-Small Cell Lung Cancer: Challenges and Perspectives

  2025cites this paper